CRMD
CorMedix Inc.
CRMD trails on the overall score without a compensating advantage in the available component scores.
NVO
Novo Nordisk A/S
NVO has the edge over CRMD overall, supported by lower modeled downside and stronger modeled upside.
CRMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
CRMD's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CRMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.5x | $2.52 | -48% |
| Fair | 3.9x | $2.83 | -41% |
| Current | 6.6x | $4.84 | — |
| Expensive | 18x | $13.42 | +177% |
Historical ranges are pointers, not guarantees.
CRMD's PE is in its expensive range at 6.6x.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over CRMD in the historical PE scenario, which offers more potential upside but is not a forecast.
CRMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect CRMD's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
NVO has the edge over CRMD on the outlook, with more favorable earnings and revenue expectations.
CRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.73 | -65% |
| Q2 2026 | $2.18 | +179% |
| Q1 2026 | $2.17 | +768% |
| Q4 2025 | $2.04 | +$2.34 |
| Q3 2025 | $2.09 | +$2.89 |
| Q2 2025 | $0.78 | +$1.70 |
| Q1 2025 | $0.25 | +$1.17 |
| Q4 2024 | -$0.30 | +$0.61 |
CRMD earned $0.73 per share over the past year, down 65% from the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CRMD on earnings, with more consistent year-over-year improvement.
CRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.5M | -48% |
| Q2 2026 | $101.9M | +157% |
| Q1 2026 | $127.4M | +226% |
| Q4 2025 | $128.6M | +312% |
| Q3 2025 | $104.3M | +810% |
| Q2 2025 | $39.7M | +4829% |
| Q4 2022 | $29.7K | -47% |
| Q3 2022 | $6.8K | -82% |
CRMD's revenue is growing: $55M last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12% | -61 points |
| Q2 2026 | 42% | -7.1 points |
| Q1 2026 | 50% | -1.5 points |
| Q4 2025 | 46% | +4.5 points |
| Q3 2025 | 49% | +78 points |
| Q2 2025 | 49% | +1947 points |
| Q1 2025 | 52% | N/A |
| Q4 2024 | 41% | N/A |
CRMD's operating margin was −12% last quarter, down 61 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CRMD on profitability, with a higher operating margin.
CRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $87.8M | +189% |
| Q2 2026 | $85.7M | +186% |
| Q1 2026 | $41.7M | +111% |
| Q4 2025 | $92.7M | +$98.4M |
| Q3 2025 | $30.4M | +$44M |
| Q2 2025 | $30M | +$44M |
| Q1 2025 | $19.7M | +$37.1M |
| Q4 2024 | -$5.6M | +$5.4M |
CRMD has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
CRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -15% | -14M shares |
| 1 year | +9.1% | +6.5M shares |
| 3 years | +73% | +33.1M shares |
| 5 years | +106% | +40.4M shares |
| Available history | +225% | +54.3M shares |
CRMD has 78M diluted shares, up 9.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $6.4M |
| Q1 2026 | $11.1M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CRMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.8x | Net Cash |
| Q2 2026 | -1.0x | Net Cash |
| Q1 2026 | -0.8x | Net Cash |
| Q4 2025 | -0.9x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -3.2x | Net Cash |
| Q1 2025 | -4.5x | Net Cash |
CRMD has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.4 | Oversold |
| Stochastic | 2.7 | Oversold |
CRMD's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CRMD PE vs Healthcare Sector
| Metric | CRMD | Sector median | Relative |
|---|---|---|---|
| PE | 6.6x | 26x | 74% below |
| PE % | 66 | 29 | 37 pts above |
CRMD has the edge over NVO on valuation relative to its sector.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.67 | 27% below |
| 20 week MA | $7.49 | 35% below |
| 50 week MA | $7.91 | 39% below |
| 100 week MA | $9.41 | 49% below |
| 200 week MA | $7.22 | 33% below |
CRMD is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over CRMD on trend strength, trading above more of its moving averages.
CRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.14 | $7.87 | +10% |
| 2021 | $7.87 | $4.98 | -37% |
| 2022 | $4.98 | $4.11 | -17% |
| 2023 | $4.11 | $3.76 | -8.5% |
| 2024 | $3.76 | $8.21 | +118% |
| 2025 | $8.21 | $12.5 | +53% |
| 2026 YTD | $12.5 | $4.84 | -61% |
CRMD has finished lower in three of the last six years. It's down 61% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CRMD on returns for 2026, with the stronger performance.